rss

Germany to revise higher 2020 GDP forecast, expect weaker rebound in 2021

Reuters reports, citing two sources familiar with the matter

Germany
  • 2020 GDP forecast to be revised to -5.8%; previously -6.3%
  • 2021 GDP forecast to be revised to +4.4%; previously +5.2%
These are the same figures as what Der Spiegel is reporting here. German economy minister, Peter Altmaier, is going to present the latest figures later today at ~0900 GMT.

Eurozone August final manufacturing PMI 51.7 vs 51.7 prelim

Latest data released by Markit – 1 September 2020

The preliminary release can be found here. This just confirms that factory activity held up somewhat in August across the euro area, keeping on the recovery path.
However, there are ongoing concerns surrounding domestic demand conditions and amid the hit to the services sector last month, it continues to allude to a considerable degree of uncertainty involving the virus situation in general.
We’ll have to see how things go in the coming months for a better idea on how the recovery is progressing within the region. Markit notes that:

“Eurozone factory output rose strongly again in August, providing further encouraging evidence that production will rebound sharply in the third quarter after the collapse seen at the height of the COVID19 pandemic in the second quarter. Business expectations for output in a year’s time also rose to the highest for over two years as prospects continued to brighten from the unprecedented gloom seen earlier in 2020.

“Caution is warranted in assessing the likely production trend, however, as so far it would have been surprising to have seen anything other than a rebound in output and sentiment. Worryingly, order book growth cooled slightly in August, and there are indications that firms are bracing for a near-term weakening of demand.

“Of note, a key theme of the latest survey is one of firms taking a cautious approach to costs and spending, notably in respect to investment and hiring, amid continued worries about the strength of future demand and uncertainty over the course of the pandemic. Producers of investment goods such as plant and machinery reported the weakest order book growth, and job losses remained amongst the most prevalent since the global financial crisis.

“Whilst the drop in payroll numbers was led by Germany, France, Spain and Austria reported a reacceleration of job losses and a return to job cutting was seen in Ireland, sending worrying signals that many firms have become more concerned about the near-term outlook.

“In short, manufacturing is currently being buoyed by a wave of pent up demand, but capacity is being scaled back. The next few months’ data will be allimportant in assessing the sustainability of the upturn.”

Nikkei 225 ends the day flat at 23,138.07

Japanese stocks close pretty much flat on the day

Nikkei 01-09

Asian equities are seeing rather muted tones in general, though they are off earlier lows at least but are failing to find much inspiration after the mixed tones in Wall St overnight.

The Hang Seng is also flat on the day currently, while the Shanghai Composite is down slightly by 0.1%. US futures are off earlier lows to sit around ~0.2% higher now.
Elsewhere, the mood among major currencies is still siding against the dollar with the greenback lagging across the board. EUR/USD is hovering just under 1.2000 as we look towards European trading while USD/CAD is nearing the 1.3000 handle.

China – Caixin/Markit Manufacturing PMI for August: 53.1 (expected 52.5)

Caixin/Markit Manufacturing PMI for August comes in stronger than expected and up from July at 53.1, 4th consecutive month in expansion

  • expected 52.5, prior 52.8
Highest since January of 2011
  • New export orders a notable improvement, first growth for this year
  • Sharpest increases in output and new orders since the start of 2011
  • Employment moves closer to stabilisation
Dr. Wang Zhe, Senior Economist at Caixin Insight Group (this in summary):
  • overseas demand started to pick up
  • new export orders entered expansionary territory for the first time this year, due mainly to the slowing spread of the pandemic overseas
  • Companies were willing to replenish their stocks as demand continued to expand
  • Employment remained subdued … employment subindex stayed in negative territory for the eighth consecutive month, but it was the closest to positive territory this year
  • backlogs of work expanded at a faster pace than the previous month, which could be seen as a positive signal that a turning point is approaching for employment.  Input costs and output prices both rose, albeit at a slower pace
“Overall, the post-epidemic economic recovery in the manufacturing sector continued. Supply and demand expanded with the pickup in overseas demand. Backlogs of work continued to increase. Both quantity of purchases and stocks of purchased items also grew. Companies’ future output expectations remained strong, reflecting a positive outlook for the manufacturing sector for the year ahead. Employment remained an important focus. An expansion of employment relies on long-term improvement in the economy. Macroeconomic policy supports are essential, especially when there are still many uncertainties in domestic and overseas economies. Relevant policies should not be significantly tightened.”

Japan politics – chief cabinet secretary Suga to declare candidacy for PM position

Japanese Prime Minister Abe is resigning due to health issues.

Suga is reportedly set to announce his candidacy for the top job on Wednesday.

I said yesterday that of the candidates Suga is likely the ‘steady-hand’ candidate for markets. his role as chief cabinet secretary has had him addressing media (and therefore markets) throughout Abe’s prime ministership.

AstraZeneca plans its vaccine test on 50,000 enrolment

AstraZeneca Plc has begun a large-scale human trial of its coronavirus vaccine in the US

Earlier reports said the company planned to test on 30K but the latest is it’ll be a test on over 50k. 30k in the US, 20k elsewhere around the globe.
In the US the tests are being conducted with the assistance of the University of Wisconsin School of Medicine and Public Health as one of the sites for the human trials. The plan is to begin trials with the volunteers on Tuesday, with tests to accelerate following the September 7 US Labor Day holiday.
How the tests will be conducted, in brief:
  • adults aged 18 years or over
  • from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus
  • participants are being randomized to receive two doses of either AZD1222 or a saline control, four weeks apart
  • twice as many participants receiving the potential vaccine than the saline control
  • trial is assessing the efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.
  • late-stage clinical trials are ongoing in the UK, Brazil and South Africa and trials are planned to start in Japan and Russia.
Adds the company (bolding is mine):
  • Results from the late-stage trials are anticipated later this year, depending on the rate of infection within the clinical trial communities.
  • In July 2020, interim results from the ongoing Phase I/II COV001 trial were published in The Lancet and showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
AstraZeneca Plc has begun a large-scale human trial of its coronavirus vaccine in the US
Go to top